Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7303509 in systemic sclerosis
NCT05462522Phase 1Completed
- Sponsor
- Genentech
- Start
- Jan 2023
- Primary completion
- Jul 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 1, randomised, double-blind trial of ro7303509 in systemic sclerosis (SSc) (3 arms), sponsored by Genentech. Primary endpoints: Participants With Treatment Emergent Adverse Events at 17 months, Change From Baseline in Vital Signs at 17 months and 2 more. Started Jan 2023; status: completed.
02
Drugs
ro7303509
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT05462522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05462522.